PRAME Antikörper (AA 321-509)

Produktnummer ABIN1589821

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch PRAME in WB. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für PRAME Antikörper (AA 321-509) (ABIN1589821)

Target: PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser PRAME Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Produktdetails anti-PRAME Antikörper

Bindungsspezifität: AA 321-509

Verwendungszweck: PRAME antibody

Spezifität: Recombinant human PRAME (Met321-Asn509)

Immunogen: Recombinant human PRAME (Met321-Asn509)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Western Blot: Use 1-5 μg/mL

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.

Buffer: PBS

Handhabung: Centrifuge vial prior to opening.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.

Haltbarkeit: 24 months

Details zu PRAME

Target: PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))

Andere Bezeichnung: PRAME

Hintergrund: Melanoma antigen preferentially expressed in tumors, Opa-interacting protein 4, MAPE, OIP4,PRAME/MAPE/OIP4 is a germinal tissue-specific gene that is also expressed at high levels in haematological malignancies and solid tumors. The physiological functions of PRAME in normal and tumor cells are unknown, although a role in the regulation of retinoic acid signaling has been proposed. Sequence homology and structural predictions suggest that PRAME is related to the Leucine-rich repeat (LRR) family of proteins, which have diverse functions. PRAME, or ""preferentially expressed antigen in melanoma"", was originally identified as a gene encoding a HLA-A24 restricted antigenic peptide presented to autologous tumor-specific cytotoxic T lymphocytes derived from a patient with melanoma. PRAME is synonymous with MAPE (melanoma antigen preferentially expressed in tumors) and OIP4 (OPA-interacting protein 4), and its expression profile defines it as a cancer-testis antigen. Cancer-testis antigens (CTAs) are encoded by non-mutated genes expressed at high levels in germinal tissues and tumors, but which are absent from or detected at low levels in other tissues. PRAME may be somewhat different to other cancer-testis antigens in that it shows some expression in normal tissues such as ovary, adrenal, placenta and endometrium. The C-terminus of human PRAME (amino acids 453-509) was also identified to bind Neisseria gonorrhoeae opacity factors, in this case the OPA-P protein. Thus PRAME is also known as OIP4 (OPA interacting protein),

Gen-ID: 23532

NCBI Accession: NM_006115, NP_006106

UniProt: P78395

Pathways: Retinoic Acid Receptor Signaling Pathway, Nuclear Hormone Receptor Binding